Ascentage Pharma Group InternationalvsMerck & Company

AAPG and MRK stock compared: price, dividend, valuation and results, from SEC filings.

AAPG

Ascentage Pharma Group International

$11.97

Value $1.1B

-3.78%
AAPG's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

Ascentage Pharma Group International (AAPG) has a market value of $1.1B and Merck & Company (MRK) $331B. Over the last year, with dividends, AAPG moved -62.8% and MRK +44.8%. Dividend yield: AAPG none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AAPG$1.1B

    MRK$331B

    MRK is 296 times AAPG

  • Revenue, 12 months

    AAPG$82M

    MRK$67.4B

    MRK is 821 times AAPG

  • Net income, 12 months

    AAPG-$178M

    MRK$2.5B

  • Operating margin

    AAPG-215.3%

    MRK–

  • ROIC

    AAPG-73.2%

    MRK3.9%

    77.1 points apart

  • P/E

    AAPG–

    MRK134.8

  • Dividend yield

    AAPG0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AAPG-62.8%

MRK+44.8%

50100150DecFebAprJunAugOct
Returns by period
PeriodAAPGWith dividendsMRKWith dividends
1 year since November 19, 2025-62.8%Price -62.8%+44.8%Price +40.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AAPGAscentage Pharma Group InternationalMRKMerck & Company

Valuation

AAPGMRK
Valuation
Price$11.97$133.72
Market value$1.1B$331B
Enterprise value (EV)$946M$375B
P/E–134.8
P/E, 5-year median–14.8
P/B5.97.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

AAPGMRK
Results and growth
Revenue, 12 months$82M$67.4B
Net income, 12 months-$178M$2.5B
Free cash flow, 12 months-$172M$14.7B
Earnings per share, 12 months-$2.00$0.98
Revenue growth, year on year-41.5%1.3%
Revenue growth a year, past+39.9%over 3 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

AAPGMRK
Margins and returns on capital
Gross margin91.5%71.8%
Operating margin-215.3%–
Net margin-216.5%3.6%
ROIC-73.2%3.9%
ROE-93.2%5.2%

Balance sheet

AAPGMRK
Balance sheet
Cash$171M$9.7B
Total debt–$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

AAPGMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AAPG or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Ascentage Pharma Group International or Merck & Company?

By market value, Merck & Company ($331B) is about 295.9 times Ascentage Pharma Group International ($1.1B), at today's prices.

How did AAPG and MRK stock do over the last 1 years?

Since November 19, 2025, AAPG's price moved -62.8% and MRK's +40.7%. With dividends: AAPG -62.8% (-62.8% a year), MRK +44.8% (+44.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, AAPG or MRK?

The dividend yield at today's price is none for Ascentage Pharma Group International and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Ascentage Pharma Group International or Merck & Company?

Over the last twelve months, the net margin was -216.5% for Ascentage Pharma Group International and 3.6% for Merck & Company, and the operating margin -215.3% and –. Revenue was $82M and $67.4B.

Which is the better investment, Ascentage Pharma Group International or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.